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Introduction: National Member Organisations (NMO) of persons with haemophilia (PWH) from the DACH
Region (D = Germany, A = Austria, CH = Switzerland) were interested to better understand PWH’s expectations
and concerns of extended half-life (EHL) factor concentrates (FC) before availability in these countries.
Methods: Based on an expert meeting and focus groups conducted across Germany a survey for haemophilia
patients and their parents was developed and was sent out to 2,644 PWH. Results: One thousand and seven
questionnaires were sent back (38.1%); 743 adults and 262 parents. Most patients had haemophilia A (84.5%),
were severely affected (73.7%), received prophylaxis (57%) and used recombinant FC (60.2%). One-quarter did
not know the correct half-life of their FC [HA/FVIII: 26%, HB/FIX: 31.1%]. Four percent were unsatisfied with
their current FC, mainly with short half-life of FC and difficult manageability. They expected from new EHL
products less frequent injections (55.2%), better efficacy (32.1%) and safety/no side effects (15.7%); 59.5%
would be willing to switch to new products if they have a prolonged half-life and the same safety of the current
FC. They wish more information about half-life (84.4%), possible side-effects (81.3%) and efficacy (77%) and
wanted to receive information about new products from their haemophilia treater (76.3%) and the newsletter of
their NMO (74.3%). Significant differences across countries were found. Conclusions: The representative survey
could show that although PWH were generally satisfied with their current FC, the majority would be willing to
switch to EHL products assuming half-life is prolonged and has the same safety of the current FC.
Keywords: DACH Region, expectations, extended half-life, haemophilia, long-acting factor concentrates, patients’
needs, survey
Introduction
Most haemophilia patients in Western Europe nowadays
have the opportunity to get regular prophylaxis [1] and
can live normal lives due to the sufficient availability and
funding of plasmatic and recombinant factor concen-
trates (FC) [2,3]. Several studies have shown the advan-
tages of prophylaxis over episodic therapy. In young
children prophylaxis could prevent joint damage
compared to episodic treatment [1,4,5]. Adult patients
on prophylaxis showed significantly less physical pain,
had better general health, less severe bleeds, less disease
progression, and reported significantly better health-
related quality of life compared to those on episodic
treatment [6,7]. The aim of regular prophylaxis is to
maintain factor levels ≥1% [8]. But there is no clear cor-
relation between trough levels and bleeding events as
some persons with haemophilia (PWH) bleed with
trough levels >1%, while others experience no bleeds
with trough levels <1% [9]. Therefore, trough levels are
at least as important as other parameters such as clinical
outcomes to find the optimal treatment regimen. Regular
factor VIII concentrates have short half-lives of in aver-
age 12 h [10], although there is a high inter-individual
variability (6–29 h) [11,12]. Therefore, the majority of
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haemophilia A (HA) patients inject themselves every
other day to three times per week [8]. With an average
factor IX half-life of 18–24 h most haemophilia B (HB)
patients inject themselves twice per week [13]. It could
be demonstrated that the burden of frequent injection
with the regular existing FC was one of the major obsta-
cles to adherence in adolescents and adults [14,15]. In
younger children, administration of FC is particularly
demanding. Children have often difficult venous access,
parents may be reluctant to administer the FC to the
own child, and the reconstitution and administrations in
the morning before school and going to work may
become very stressful. Moreover, it was shown that care-
givers who spent more than 8 h for injecting their hae-
mophilic children in the previous month perceived a
greater burden [16]. Poor treatment adherence can lead
to increased annual bleeding rate (ABR) [9,17]. Last, but
not least adherence was shown to be correlated with age
of haemophilia patients [18,19].
The new, up-coming extended half-life (EHL) FC
for treatment of HA and HB may have the potential
to reduce injection frequency, to increase protection
and to improve patients’ quality of life [20–23]. Little
is known about patients’ perspectives on the use of
these new FC [24] and their willingness to switch to
these products.
The role of the national member organisations
(NMO) of haemophilia patients is to support and
advise their members, e.g. concerning novel therapies,
to facilitate access to treatment, to provide patients’
perspectives and to inform the general population
about haemophilia. They are voluntary groups where
everybody with interest in bleeding disorders can
become a member. The number of families with hae-
mophilia in the NMOs varies with respect to the total
haemophilia population across the countries. In Ger-
many there are 1,499 haemophilia members represent-
ing approximately 18.3% of the expected national
haemophilia population, in Switzerland 404 (50.5%),
and in Austria 487 (57.5%), respectively.
National Member Organisations of the DACH
Region (D = Germany, A = Austria; CH = Switzer-
land) were interested to better understand what
patients already know about the new FC with EHL,
if there is a real need for these FC in the haemophi-
lia community and to what extent PWH would
switch to these new products. Furthermore, the
patient organisations wanted to learn about the
PWHs expectations and concerns about these new
FC in order to adapt their support for the haemo-
philia community.
Study design and methods
The study consisted of two phases: (i) conduct of an
expert meeting and separate focus groups with adult
haemophilia patients and parents of haemophilic
children in order to gather some insight into patients’
expectations of new EHL FC and their unmet needs;
(ii) systematic postal survey among all registered mem-
bers with HA or HB of the NMOs of the DACH
Region.
Expert meeting
An expert meeting was performed with representatives
of the German NMO and a leading haemophilia trea-
ter in order to discuss the study outline and the ques-
tions for the focus groups.
Focus groups
Five separate focus groups with adult haemophilia
patients and parents of children with haemophilia
were conducted regarding new EHL products. Focus
groups were based on semi-structured interviews (last-
ing 1.5–2 h each) and contained 12 questions concern-
ing patients’ current treatment, information about
treatment options and how products are chosen. Focus
groups took place across Germany in Hamburg
(adults), Cologne (adults), Munich (children) and
Dresden (adults; children) in a total of 32 participants.
Concepts that emerged during the discussions were
reformulated into questions/items and respective
answer categories and included in the survey.
Questionnaire survey
Based on the findings of the focus groups a modular
survey was constructed with questions concerning the
following aspects: (i) demographic and clinical data
of the patient, (ii) knowledge about half-life of cur-
rent FC, (iii) attitudes towards FC (a) satisfaction
with current FC, (b) expectation of new EHL prod-
ucts, (c) willing to switch to new EHL products, (d)
required information for decision making, (e) pre-
ferred information sources, (f) facilitation of therapy
in general.
Recruitment and inclusion criteria
All patients with HA or HB and caregivers of hae-
mophilic children registered at the NMOs of the
DACH Region were contacted via a letter of their
NMO asking to complete the attached survey and
to send it back anonymously. Patients were
informed that their data would be published and
that they would give automatically their informed
consent by sending back the completed question-
naire. Since this survey was conducted by the
NMOs, no ethical approval was requested by the
ethics committees of the three countries. The system-
atic postal survey was sent out to 2,644 patients
and parents of children with HA or HB in Germany
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(January-March 2015), Switzerland (January-March
2016) and Austria (June-August 2016).
Statistical analysis
Qualitative analysis. Open questions were clustered
in thematic aspects based on an inductive approach of
category development [25]. The emerged clusters were
then counted for their frequencies.
Quantitative analysis. All statistical analyses were
conducted using the SPSS program versions 23/24
(SPSS Inc. Chicago, IL, USA). Descriptive data are
shown as frequency distribution in percent or as
mean  standard deviation (M  SD), median and
range. The comparison of differences between
groups was examined using univariate ANOVA, Stu-
dent’s t-test or Chi-square tests depending on the
distribution of the data; P values <0.05 were defined
as significant.
Results
Focus groups
Three out of five focus groups were conducted with
23 adult PWH (mean age 40.96  17.3 years, range
19–71) and two with nine parents of children with
haemophilia ranging from 4 to 19 years. From the
parents (mean age 45.11  5.1 years, range 39–52)
55.6% were mothers. The majority of patients had
HA (81.3%), were severely affected (78.1%) and
used recombinant FC (68.7%); 77.8% of paediatric
and 69.6% of adult patients received prophylactic
treatment. In general PWH and parents of children
with haemophilia were satisfied with their current
product, few complaints (n = 6) were mentioned due
to size of package, volume, non-availability of the
products when travelling, and insufficient prevention
of bleeding. PWH would like to see improvement in
the half-life (43.8%), package (size, completeness,
logistic) (40.6%), and stability at ambient tempera-
tures (18.8%). PWH had almost no information
about up-coming EHL products, wished more infor-
mation about dosing and safety, and would be will-
ing to change FC, if the new FC shows increased
benefit and a significantly increased half-life.
Postal survey
From a total of 2,644 contacted PWH with HA
or HB in Germany, Switzerland and Austria 1,013
questionnaires were sent back (38.3%). Five
patients had to be excluded from further analysis
since they had VWD (n = 4), or FVII deficiency
(n = 1). In total 1,007 questionnaires were anal-
ysed (38.1%).
Demographic and clinical data
Seven hundred forty three adult PWH and 262 parents
of haemophilic children participated, two respondents
could not be classified. The majority of these adult
patients and parents were between 40 and 49 years
old, while children were between 6 and 12 years old
(Table 1).
The majority of all PWH had HA (84.5%), were
severely affected (73.7%) and received regular prophy-
laxis (57%), mainly three times per week (47.4%),
and 60.2% used recombinant FC (HA: 65%, HB:
34.2%), 14.9% of patients had an inhibitor (current
or past) (Table 2).
Knowledge about half-life of current factor
concentrates
Fifty-one percentage of all patients reported the cor-
rect half-life of FVIII concentrates, while only 12.4%
knew the correct half-life of FIX concentrates. Com-
paring HA with HB patients we found that more than
one quarter of patients and parents did not know the
correct half-life of their current FC (HA: FVIII: 26%,
HB: FIX: 31.3%) (Fig. 1).
Patients (55.1%) with severe haemophilia reported
the correct half-life of FVIII compared to only 39.9%
of patients with mild/moderate haemophilia (v2:
39.133, P < 0.0001).
Table 1. Demographic data of all respondents (n = 1007).
Respondents*
All (n = 1007)
N Percentage
Haemophilia patients 743 73.9
Mothers of children with haemophilia 211 21.0
Fathers of children with haemophilia 36 3.6
Both parents together 14 1.4
Stepmother 1 0.1
Age categories*
Parents (n = 262) Adults (n = 743)
N Percentage N Percentage
<20 years 56 7.6 2 0.8
20–29 years 129 17.4 4 1.5
30–39 years 125 16.9 85 32.8
40–49 years 147 19.8 137 52.9
50–59 years 141 19.0 30 11.6
60–69 years 87 11.7 – –
≥70 years 56 7.6 1 0.4
Age categories*
Children (n = 262)
N Percentage
0–3 years 39 14.9
4–5 years 27 10.3
6–12 years 117 44.8
13–16 years 57 21.8
17–18 years 13 5
>18 years 8 3.1
*Missing data.
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Attitude towards new factor concentrates
86.6% of PWH were ‘rather satisfied’/’satisfied’ with
their current FC (n = 845), while 9.4% were ‘neither
unsatisfied nor satisfied’ (n = 91). Only 4% were
‘rather unsatisfied’/’unsatisfied’ (n = 39), mainly due
to short half-life of FC (40.6%), difficult manageabil-
ity (22.6%) and storage of FC in the fridge (12.3%).
No differences were found between the type and
severity of haemophilia.
Concerning PWH expectations of the new EHL
products, a total of 1,321 responses were given by the
756 respondents. Among these aspects, less injections
(55.2%), better efficacy (32.1%) and safety/no side
effects (15.7%) were the most frequently mentioned
(Table 3).
In total, 59.5% of PWH would be willing to switch
to EHL products, while 36.9% were still undecided
and only 3.6% were not willing to switch to a new
EHL product when available on the market. Parents
were more sceptical than adults; only 47.1% of par-
ents (n = 122) would switch to new products com-
pared to 63.8% of adult PWH (n = 464) (Fig. 2).
Table 2. Clinical data of haemophilia patients (n = 1007).
Clinical data haemophilia patients*
Children (262) Adults (n = 743) ∑ (n = 1007)
N Percentage N Percentage N Percentage
Type of haemophilia
A 218 83.5 629 84.9 847 84.5
B 43 16.5 112 15.1 155 15.5
Severity
Severe 193 74.5 544 73.3 739 73.7
Moderate 37 14.3 108 14.6 145 14.5
Mild 28 10.8 86 11.6 114 11.4
I don’t know 1 0.4 4 0.5 5 0.5
Inhibitor
No 217 83.1 612 85.8 830 85.1
Yes, in past 34 13.0 81 11.4 115 11.8
Yes, current 10 3.8 20 2.8 30 3.1
Type of treatment
On demand 53 20.2 248 33.6 301 30.0
Prophylaxis 183 69.8 387 52.4 571 57.0
Switch prophy & on-demand 19 7.3 98 13.3 118 11.8
ITI 7 2.7 5 0.7 12 1.2
Frequency of prophylaxis
Every 10–14 days – – – 0.4 2 0.2
1 times per week 12 6.0 33 7.1 45 6.7
2 times per week 33 16.4 150 32.1 184 27.4
3 times per week 102 50.7 215 45.9 318 47.4
>3 times per week 54 26.9 68 14.5 122 18.2
Product category
Plasma-derived 74 28.9 235 32.70 309 31.7
Recombinant 167 65.2 419 58.4 588 60.2
I don’t know 15 5.9 64 8.9 79 8.1
*Missing data.
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Fig. 1. Knowledge about half-life of their current factor concentrate
between haemophilia A and haemophilia A patients.
Table 3. Expected features from extended half-life products (n = 756).
Open answers categorized
Adults/Parents
(% of respondents)
Less frequent injections 417 (55.2)
Efficacy of product 243 (32.1)
Safety of product/no side effects 119 (15.7)
Improved manageability 75 (9.9)
Better quality of life (independence, flexibility) 69 (9.1)
Extended half-life 63 (8.3)
Storage of factor concentrate
at room temperature
63 (8.3)
Travel convenience 40 (5.3)
Cheaper costs 37 (4.9)
Drug tolerability 32 (4.2)
Vein protection 30 (4.0)
Different mode of administration (oral, sc) 27 (3.6)
Longer shelf-life 22 (2.9)
Once a week injection 21 (2.8)
Other aspects* 63 (8.3)
*Other aspects: <109 mentioned (availability, smaller package, bigger
units, switch to prophylaxis, not tested sufficiently, etc.)
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Reason for willingness to switch to new FC were
prolonged half-life/dosing interval (87.1%), same
safety of the current FC (62.8%), and if they are tra-
vel friendly (61.8%) (Table 4). Parents and adults
showed significantly different preferences for stability
at ambient temperatures (v2: 12.237, P < 0.0001),
motivation to switch to prophylaxis (v2: 6.292,
P < 0.012), beneficial for sport (v2: 19.805,
P < 0.0001) and experience in practical use (v2:
10.100, P < 0.001). No difference was found for dif-
ferent severities.
Reasons for not willing to switch were fear of inhi-
bitor development (71.4%) and fear of uncertain
safety (60.9%). Differences between adults and par-
ents were found for fear of inhibitor development (v2:
22.477, P < 0.0001), fear of uncertain safety (v2:
4.290, P < 0.038) and immediate availability of the
current FC (v2: 5.092, P < 0.024; Table 5). The same
significant differences regarding willingness to switch
or not to switch were also found when comparing the
different severities.
Respondents would consider changing product if the
prolongation of half-life is at least double as high as
the current FC (40.5%) (Fig. 3).
Significant differences were found between mild/
moderate vs. severe treatment (v2: 17.994, P < 0.021),
3,2
63,8
33
Patients
no yes perhaps
%
%
% 5
Parents
no yes perhaps
(n = 464)
(n = 23)
(n = 240)
(n = 13)
47,1
47,9
(n = 122)
(n = 124)
%
%
%
Fig. 2. Willingness to switch from current pro-
duct to new extended half-life product [adult
patients (n = 743), parents (n = 262)].
Table 4. Reasons to switch to new extended half-life products (adult
patients, parents).
Reasons for switching
(multiple answers possible)
Adults
N (%)
Parents
N (%) P-value
Longer half-life/dosing
interval of new product
555 (86.7) 192 (88.9) ns
More security when travelling
for a short period
405 (63.3) 123 (56.9) ns
Same safety of new product 392 (61.3) 146 (67.6) ns
New product advantages
for surgery
335 (52.3) 97 (44.9) ns
Longer stability at ambient
temperatures of new product
328 (51.3) 81 (37.5) 0.0001
Better efficacy of new product 322 (50.3) 100 (46.3) ns
New product beneficial
for doing sport
285 (44.5) 134 (62.0) 0.0001
Easier application of new product 209 (32.7) 80 (37.0) ns
Lower price of new product 134 (20.9) 54 (25.0) ns
Motivated to switch to
prophylaxis with new product
100 (15.6) 19 (8.8) 0.012
Sufficient experience
in practical use
82 (12.8) 47 (21.8) 0.001
Other reasons 28 (4.4) 13 (6.1) ns
In bold are significant differences in the preference between adults and
parents.
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Fig. 3. Half-life prolongation time to consider switching product (adult
patients, parents).
Table 5. Reasons NOT to Switch to New EHL Products (adult patients,
parents).
Reasons for NOT switching
(multiple answers possible)
Adults
N (%)
Parents
N (%) P-value
Fear of inhibitor
development of new product
83 (59.7) 87 (87.9) 0.0001
Fear of uncertain safety
of new product
77 (55.4) 68 (68.7) 0.038
No side effects of current product 76 (54.7) 50 (50.5) ns
Satisfaction with current product 68 (48.9) 36 (36.4) ns
Lack of transparency of
info of new product
45 (32.4) 27 (27.3) ns
Good manageability
of current product
33 (23.7) 17 (17.2) ns
Immediate availability
of current product
33 (23.7) 12 (12.1) 0.024
No advantage to change product 21 (15.1) 7 (7.1) ns
Other reason 9 (6.5) 4 (4.0) ns
In bold are significant differences in the preference between adults and
parents.
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on-demand vs. prophylaxis treatment (v2: 18.424,
P < 0.018) and plasma-derived vs. recombinant prod-
ucts (v2: 20.107, P < 0.010). No difference was found
between HA and HB patients.
In order to make an adequate decision to switch
PWH wished more information about half-life
(84.4%), possible side-effects (81.3%) and efficacy
(77%).
The majority wanted to receive information about
new products from their haemophilia treater (76.3%)
and the newsletter of their NMO (74.3%), followed
by an information letter by their HTC/NMO (35.7%),
internet (22%), patient brochure (21.3%) and NMO
patient meeting (20.9%).
Facilitation of therapy in general
When asking how the therapy could be facilitated,
568 PWH mentioned in total 737 aspects. Most
PWHs said that they would like to have smaller/differ-
ent type of packages (33.8%), better manageability
(device, syringe, etc.) (29%), different mode of admin-
istration (oral, s.c., gene therapy, permanent vein
access, etc.) (19.9%), and storage at ambient tempera-
tures (15.5%).
Differences across the countries of the DACH
Region
A significant difference across the countries in the
DACH Region was found concerning treatment regi-
men (v2: 44.670, P < 0.0001) and product category
(v2: 30.391, P < 0.0001). In Germany (61.4%) and
Austria (61.6%) more PWH received prophylaxis,
while in Switzerland (58.3%) PWH received on-
demand treatment. Whereas in Switzerland (65.2%)
and Austria (67.8%) more patients used recombinant
products compared to Germany (57.8%); in Germany
6% did not know which product category they used
compared to 14% in Switzerland and 10.3% in Aus-
tria. Although there was a higher use of recombinant
products in HA patients in all countries (DE: 62.4%,
CH: 70.3%, A: 71.4%), there was a significant differ-
ence across countries (v2: 34.673, P < 0.0001).
The willingness to switch to EHL products was sig-
nificantly different across countries (v2: 22.212,
P < 0.0001); parents in Austria and Germany were
more conservative, only 33.3% and 44% respectively
were willing to switch to EHL products while in
Switzerland 61.7% of parents were willing to do so
(Fig. 4).
Significant differences were found as well for
required information. More Germans needed informa-
tion concerning side effects (v2: 11.987, P < 0.002)
and supply guarantee (v2: 31.005, P < 0.0001),
whereas more Swiss needed information about costs
(v2: 19.389, P < 0.0001) and launch time (v2: 7.027,
P < 0.003) and more Austrians about efficacy (v2:
9.507, P < 0.009).
For Germans and Swiss the most important source
of information was the haemophilia treater (v2: 9.433,
P < 0.009), whereas for Austrians it was the NMO
newsletter (v2: 25.543, P < 0.0001). More Swiss
PWH considered an information letter from the HTC/
NMO (v2: 17.941, P < 0.0001) and a patient bro-
chure (v2: 6.382, P < 0.041) as important information
3,3
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Fig. 4. Willingness to switch from current product to new extended half-life product across countries (adult patients, parents).
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sources, while more Germans considered an info meet-
ing from their HTC (v2: 22.350, P < 0.0001) as
important.
Discussion
Patients from the DACH Region had limited knowl-
edge about the new EHL FC. Even though the major-
ity of patients were satisfied with their current FC, a
significant number of patients were willing to switch
to new EHL products when certain features of the
products were fulfilled. Short half-life and the correlat-
ing frequent injections were the major perceived disad-
vantages of the current products. On the other hand
patients and their parents would not compromise on
safety or protection but also did not expect them to
be better. Differences in the countries showed higher
prophylaxis in Germany and Austria and a higher rate
of recombinant FC use in Switzerland and Austria.
Swiss parents were a lot more willing to switch their
children to EHL products compared to the other
countries. For Swiss patients pricing was an important
topic while in Germany and Austria travel conve-
nience, sufficient experience in practical use and
advantages for surgery were more important.
Up to one-third of patients from the DACH Region
reported not to know the half-life of their FC this
result is in line with the findings of a Swedish study in
which haemophilia patients had limited knowledge
about their disease and treatment, and demonstrated
the importance of continually providing information
about haemophilia and it’s treatment [26]. Canadian
health care providers underlined this in their statement
‘provision and uptake of disease knowledge is essen-
tial to patient self-management’. The authors claimed
that PWH require the right information, from the
right source, at the right time and advocated that edu-
cation should be tailored to the needs of PWH [27].
Most PWH in the DACH Region expected from the
new EHL products to provide less frequent injections
and to be effective. Burden of frequent injections with
the regular existing FC is considered one of the major
obstacles to adherence in children and adults [14,15].
Although a high adherence rate was found among
397 prophylactically treated haemophilia patients
(0–80 years) in Germany, the authors concluded that
frequent venous punctures and time spent to inject FC
lead to treatment burden and therefore to non-adher-
ence to prophylaxis [19]. In a US discrete-choice sur-
vey preferences of PWH and willingness to pay (WTP)
were assessed for on-demand, prophylaxis, and longer
acting prophylaxis therapies. Dosing frequency and
treatment effectiveness were considered important for
treatment-related decisions. The authors concluded
that the positive preferences and WTP for longer act-
ing prophylactic therapies is likely to increase adher-
ence and improve treatment outcomes [28]. The new,
up-coming EHL products for treatment of HA and
HB will possibly reduce injection frequency. Thus,
these new FC may have the potential to significantly
improve adherence and, consequently, to increase pro-
tection and to improve patients’ quality of life [18,20–
23]. No difference was found between HA and HB
patients concerning their preference of the half-life
extension in order to switch to new EHL products.
This might be due to the fact that patients do not
really have a clear concept of what half-life means
and what are the potential benefits of new EHL prod-
ucts. On the other hand it could be interpreted that
HB patients are aware of the potential benefits of FIX
products having a 4–5 fold half-life extension and
therefore no difference was found.
These surveys have potential limitations. The sur-
veys were conducted at different time points; Germany
participated 1 year earlier, which could have an influ-
ence on the knowledge about half-life and expecta-
tions of new EHL products. This time gap was due to
the fact that the survey was initially only planned to
be conducted in Germany. Only after the analysis of
the data we planned to extend the survey to Switzer-
land and Austria in order to get a better insight of the
entire DACH Region and to investigate whether there
were country differences. Even if a representative
number of patients were answering the survey there is
always a bias if these patients are more interested and
more active patients and if those patients who did not
respond could show a very different picture of the sit-
uation. The interpretation of the results of the ques-
tion of what half-life prolongation the product should
have was very controversially discussed as around one
quarter of patients did not know the correct half-life
of their current product. The question arose, what did
they expect from a 2 fold half-life extension? Espe-
cially, as the majority wished to have fewer injections.
Would one injection less per week, what is at least
achievable with every EHL product in HA and HB, be
the threshold for conversion? With future surveys in
this area and the findings in this survey we should
deepen our understanding on treatment burden
regarding the injection frequency.
We believe that there is a great need of better edu-
cation of PWH regarding half-life, trough level and
different options for use of EHL products. A first step
into the development of educational material was the
development of a neutral patient presentation and a
patient brochure under the patronage of the DHG and
its members of the medical advisory board.
The information gap on what PWH expect from
new EHL products could be diminished at least for
the DACH Region. Compared to other studies in hae-
mophilia where in 21 European countries in total
1,400 PWH were evaluated [29], this survey with
more than 1,000 PWH from only three countries
depicts a quite representative picture of the real-life
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situation and needs of PWH towards EHL FC in this
region. Furthermore, it would be interesting to com-
pare these findings with other European countries.
PWH are interested in current and future develop-
ments of haemophilia treatment, and wish to receive
information about novel therapies mainly from their
treaters in the haemophilia centre and via the newslet-
ter of their patient organisations. Therefore, the provi-
sion of adequate information about these therapies is
required so that patients can make an adequate deci-
sion whether they want to change their therapy to
benefit from better protection against bleeds, and a
significantly reduced treatment burden. Taking a deci-
sion regarding therapy is mainly based on evidence
from the literature and on patient preferences. One
tool here could be the shared decision-making (SDM)
process allowing patients and health care providers to
make decisions collaboratively based on available evi-
dence, and patient preferences [30].
Conclusion
In this representative survey among patients and
parents of children with haemophilia of the DACH
Region it could be shown that even though PWH
were generally satisfied with their current FC 59.5%
would be willing to switch from their current FC to
the new EHL products assuming the half-life is sig-
nificantly prolonged and has the same safety of the
current FC. One of the most unmet needs of PWH
was to reduce their treatment burden in terms of
less frequent injections, besides improved manage-
ability and better quality of life. Moreover, this sur-
vey showed new insights on how PWHs and parents
want to be informed about new products, which
information they require to be able to make a deci-
sion and from whom they wish to receive this infor-
mation. Effective communication on the advantages
and side effects of novel therapies via patient
organisations and treatments centres is the basis for
a sophisticated decision of the patient in the context
of SDM.
Acknowledgements
We would like to thank the patients and their parents who participated
in this study and the members of the Medical Advisory Board of the
DHG (Robert Klamroth, Karin Kurnik, Andreas Tiede) who critically
reviewed the results and gave input in data presentation.
Author contributions
SvM designed the study and conducted focus groups. WM contributed to
the design of the focus groups and the questions for the survey. SvM and
WK developed the questions for focus groups and constructed the ques-
tionnaire for the postal survey. DHG contacted patients for focus groups;
DHG, SHG/SHN and €OHG organised shipment of postal survey and col-
lection of questionnaires. JO, WM, MA, IP critically reviewed the data.
SvM analysed the data and wrote the paper. All authors contributed to
the paper and its revision.
Disclosures
SvM received funding to conduct focus groups and for analysing data of
the postal survey from SOBI and Baxalta/Shire. DHG and SHG received
financial support to perform the patient survey (print of questionnaires,
shipment of questionnaires, etc.) from SOBI; €OHG from Baxalta/Shire.
MA received reimbursement for attending symposia/congresses and/or
honoraria for speaking and/or honoraria for consulting from Baxalta/
Shire, Bayer, CSL-Behring, Novo Nordisk, Octapharma, Roche, and
Swedish Orphan Biovitrum. IP received occasional honoraria for lectures
and advisory board session and an unrestricted grant from CSL Behring.
JO received reimbursement for attending symposia/congresses and/or
honoraria for speaking and/or honoraria for consulting, and/or funds for
research from Baxter, Bayer, Biogen Idec, Biotest, Chugai, CSL Behring,
Grifols, Novo Nordisk, Octapharma, Pfizer, Roche and Swedish Orphan
Biovitrum.
Funding
This research was undertaken through unrestricted grants from SOBI for
the surveys in Germany and Switzerland and from Baxalta, part of Shire
for the survey in Austria.
References
1 Nilsson IM, Berntorp E, Lofqvist T, Pet-
tersson H. Twenty-five years’ experience of
prophylactic treatment in severe haemophi-
lia A and B. J Intern Med 1992; 232: 25–
32.
2 Liesner RJ, Khair K, Hann IM. The impact
of prophylactic treatment on children with
severe haemophilia. Br J Haematol 1996;
92: 973–8.
3 Khawaji M, Astermark J, Akesson K, Bern-
torp E. Physical activity and joint function
in adults with severe haemophilia on long-
term prophylaxis. Blood Coagul Fibrinoly-
sis 2011; 22: 50–5.
4 Gringeri A, Lundin B, von Mackensen S
et al. A randomized clinical trial of prophy-
laxis in children with haemophilia a (the
ESPRIT Study). J Thromb Haemost 2011;
9: 700–10.
5 Manco-Johnson MJ, Abshire TC, Shapiro
AD et al. Prophylaxis versus episodic treat-
ment to prevent joint disease in boys with
severe hemophilia. N Engl J Med 2007;
357: 535–44.
6 Royal S, Schramm W, Berntorp E et al.
Quality-of-life differences between prophy-
lactic and on-demand factor replacement
therapy in European haemophilia patients.
Haemophilia 2002; 8: 44–50.
7 World Federation of Hemophilia. Guideli-
nes for the management of hemophilia.
Available at http://www1.wfh.org/publi
cations/files/pdf-1472.pdf.Accessed Novem-
ber 2, 2016.
8 National Hemophilia Foundation, Medical
and Scientific Advisory Council. MASAC
recommendation concerning prophylaxis
(regular administration of clotting factor
concentrate to prevent bleeding), 2007.
Available at http://www.hemophilia.org/
NHFWeb/MainPgs/MainNHF.aspx?me
nuid=57& contentid=1007. Accessed
November 2, 2016.
9 Collins PW. Personalized prophylaxis. Hae-
mophilia 2012; 18(Suppl 4): 131–5.
10 Bolton-Maggs PH, Pasi KJ. Haemophilias
A and B. Lancet 2003; 361: 1801–9.
11 Fijnvandraat K, Peters M, ten Cate JW.
Inter-individual variation in half-life of
infused recombinant factor VIII is related
to pre-infusion von Willebrand factor anti-
gen levels. Br J Haematol 1995; 91: 474–6.
12 van Dijk K, van der Bom JG, Lenting PJ
et al. Factor VIII half-life and clinical phe-
notype of severe hemophilia A. Haemato-
logica 2005; 90: 494–8.
13 White GC II, Beebe A, Nielsen B. Recombi-
nant factor IX. Thromb Haemost 1997; 78:
261–5.
14 Hacker MR, Geraghty S, Manco-Johnson
M. Barriers to compliance with prophylaxis
© 2017 The Authors. Haemophilia Published by John Wiley & Sons Ltd Haemophilia (2017), 23, 566--574
PATIENTS’ EXPECTATIONS OF EHL PRODUCTS 573
therapy in haemophilia. Haemophilia 2001;
7: 392–6.
15 Richards M, Altisent C, Batorova A et al.
Should prophylaxis be used in adolescent
and adult patients with severe haemophilia?
An European survey of practice and out-
come data. Haemophilia 2007; 13: 473–9.
16 von Mackensen S, Wisniewski T, Urgo JC,
Boggio L. Pilot test of the first hemophilia-
specific burden scale for caregivers of chil-
dren with hemophilia in the United States
—the HEMOphilia associated CAregiver
Burden scale (HEMOCAB™). J Thromb
Haemost 2015; 13(Suppl. 2): PO256.
17 Berntorp E. Joint outcomes in patients with
haemophilia: the importance of adherence
to preventive regimens. Haemophilia 2009;
15: 1219–27.
18 Duncan N, Shapiro A, Ye X, Epstein J,
Luo MP. Treatment patterns, health-related
quality of life and adherence to prophylaxis
among haemophilia A patients in the Uni-
ted States. Haemophilia 2012; 18: 760–5.
19 MiesbachW,KalninsW.Adherence to prophy-
lactic treatment in patients with haemophilia in
Germany.Haemophilia 2016; 22: e367–74.
20 Carcao M. Changing paradigm of prophy-
laxis with longer acting factor concentrates.
Haemophilia 2014; 20(Suppl 4): 99–105.
21 Lillicrap D. Improvements in factor concen-
trates. Curr Opin Hematol 2010; 17: 393–
7.
22 Shapiro A. Development of long-acting
recombinant FVIII and FIX Fc fusion pro-
teins for the management of hemophilia.
Expert Opin Biol Ther 2013; 13: 1287–
97.
23 Berntorp E, Negrier C, Gozzi P, Blaas PM,
Lethagen S. Dosing regimens, FVIII levels
and estimated haemostatic protection with
special focus on rFVIIIFc. Haemophilia
2016; 22: 389–96.
24 Miguelino MG, Powell JS. Clinical utility
and patient perspectives on the use of
extended half-life rFIXFc in the manage-
ment of hemophilia B. Patient Prefer
Adherence 2014; 8: 1073–83.
25 Mayring P. Qualitative Content Analysis.
Forum: Qualitative Social Research 2000.
http://www.qualitative-research.net/index.
php/fqs/article/view/1089/2386. Accessed
March 12, 2017.
26 Lindvall K, Colstrup L, Loogna K, Wollter
I, Gr€onhaug S. Knowledge of disease and
adherence in adult patients with
haemophilia. Haemophilia 2010; 16: 592–
6.
27 Lane S, Arnold E, Webert KE, Chan A,
Walker I, Heddle NM. What should men
living with severe haemophilia need to
know? The perspectives of Canadian hae-
mophilia health care providers. Haemophil-
ia 2013; 19: 503–10.
28 Chaugule SS, Hay JW, Young G. Under-
standing patient preferences and willingness
to pay for hemophilia therapies. Patient
Prefer Adherence 2015; 9: 1623–30.
29 Schramm W, Gringeri A, Ljung R et al. ;
ESCHQoL Study Group. Haemophilia care
in Europe: the ESCHQoL study. Hae-
mophilia 2012; 18: 729–37.
30 Athale A, Giguere A, Barbara A, Krassova
S, Iorio A. Developing a two-sided inter-
vention to facilitate shared decision-making
in haemophilia: decision boxes for clini-
cians and patient decision aids for patients.
Haemophilia 2014; 20: 800–6.
Haemophilia (2017), 23, 566--574 © 2017 The Authors. Haemophilia Published by John Wiley & Sons Ltd
574 S. VON MACKENSEN et al.
